Li Xu

Li Xu is a Korean Lecturer at The Ohio State University with interdisciplinary research interests spanning neurology, oncology, and biomechanics. Their work focuses on clinical trials, medical imaging innovations, and translational research across diverse fields including autism spectrum disorder interventions, cancer immunotherapy, and ophthalmic biomechanics. Xu has contributed to studies involving neurofeedback therapy for ADHD, essential oil therapies for pediatric populations, and novel diagnostic approaches using high-frequency ultrasound elastography.

Key research areas include:

• Neurological disorders: ADHD neurofeedback, psychosis trajectory analysis, and suicide risk assessment
• Oncology: FGFR2-driven cancer treatments, immunotherapy combinations, and biomarker development
• Ophthalmology: Corneal biomechanics, optic nerve head deformation, and glaucoma mechanisms
• Biomechanical studies: Motor development in children, spinal biomechanics, and tissue elasticity analysis

Prominent recent work includes a 2025 pilot study evaluating essential oils for ASD quality of life and a 2024 phase II trial of pemigatinib for pancreatic cancer. Xu has maintained active publication output across multiple high-impact journals since 2020.